2024CUDA Conference | Professor Benkang Shi: Focus on Unmet Needs of mHSPC Patients, Achieve Stratified Treatment for Key Populations

2024CUDA Conference | Professor Benkang Shi: Focus on Unmet Needs of mHSPC Patients, Achieve Stratified Treatment for Key Populations

The current treatment status of mHSPC patients in China and the need for further improvement have drawn attention. Recently, at the "4th Annual Conference of the Urology Physicians Branch of the Chinese Medical Association (2024)" held in Beijing, Professor Benkang Shi from Qilu Hospital of Shandong University shared insights on "Long-term Management of mHSPC Patients with Novel Hormonal Therapy Schemes." Following the conference, "Oncology Frontier - Urology News" invited Professor Benkang Shi to share insights on the diagnosis and treatment status of mHSPC, stratification of key populations, and personalized treatment
2024CUDA Conference | Professor Qiang Wei: Early Initiation of Novel Hormonal Therapy Brings More Benefits to Patients

2024CUDA Conference | Professor Qiang Wei: Early Initiation of Novel Hormonal Therapy Brings More Benefits to Patients

The "4th Annual Conference of the Urology Physicians Branch of the Chinese Medical Association (2024)" was successfully held in Beijing from April 13th to 14th. During the conference, Professor Qiang Wei from West China Hospital, Sichuan University, shared insights on "Standard Treatment of mHSPC in the Era of Novel Hormonal Therapy." Subsequently, "Oncology Frontier - Urology News" invited Professor Qiang Wei to discuss the significance of early initiation of novel hormonal therapy for mHSPC patients, the comparison between dual and triple therapy, and precise treatment selection strategies.
Professor Qingyuan Zhang: Treatment Strategies for HR+/HER2- Advanced Breast Cancer Patients After Progression on CDK4/6i+ET

Professor Qingyuan Zhang: Treatment Strategies for HR+/HER2- Advanced Breast Cancer Patients After Progression on CDK4/6i+ET

While CDK4/6 inhibitors plus endocrine therapy (ET) have become the standard first-line treatment for HR+/HER2- advanced breast cancer patients, there is currently no standardized recommendation for treatment strategies after progression on CDK4/6 inhibitors plus ET. At the "2024 National Breast Cancer Conference," "Oncology Frontier" had the privilege of inviting Professor Qingyuan Zhang from Harbin Medical University Cancer Hospital to discuss the factors to consider and the available treatment strategies for patients who have progressed on CDK4/6 inhibitors plus ET.
Professor Shaohua Zhang: “CSCO BC Guidelines” Updated, Evidence-Based, Leading Chinese Clinical Practice

Professor Shaohua Zhang: “CSCO BC Guidelines” Updated, Evidence-Based, Leading Chinese Clinical Practice

The "Chinese Society of Clinical Oncology (CSCO) Breast Cancer Diagnosis and Treatment Guidelines (2024 Edition)" ("CSCO BC Guidelines") have been updated again, incorporating richer evidence-based medicine from early to late stages, introducing more new treatment strategies and options. It has influenced the field of breast cancer treatment in China significantly. "Oncology Frontier" interviewed Professor Shaohua Zhang from The Fifth Medical Center of the People's Liberation Army General Hospital to discuss the highlights and clinical significance of the updated "CSCO BC Guidelines".
2024 National Breast Cancer Congress | Professor Yingying Xu: Reflections on Translational Research Based on Neoadjuvant Platforms

2024 National Breast Cancer Congress | Professor Yingying Xu: Reflections on Translational Research Based on Neoadjuvant Platforms

Currently, neoadjuvant therapy has become an optimized treatment modality for locally advanced and some early-stage breast cancers. It can optimize local surgery by downsizing tumors and provide efficacy and prognostic information to guide adjuvant therapy, thus improving survival. Moreover, it serves as an excellent platform for personalized treatment efficacy prediction and new drug development. Translational research based on neoadjuvant platforms has significant value in selecting benefiting populations, predicting effective regimens, and achieving personalized and precise treatments. At the "2024 National Breast Cancer Congress," Professor Yingying Xu from The First Affiliated Hospital of China Medical University delivered a speech titled "Reflections on Translational Research Based on Neoadjuvant Platforms," which we will introduce in this article.
SABCS Voice of China | Professors Qiang Liu and Yaping Yang: Final Results of the National Multicenter Clinical Study on AC*4 Sequential T*4 Combined with Full-Course Dual-Target Neoadjuvant Treatment for HER2-Positive Breast Cancer Disclosed

SABCS Voice of China | Professors Qiang Liu and Yaping Yang: Final Results of the National Multicenter Clinical Study on AC*4 Sequential T*4 Combined with Full-Course Dual-Target Neoadjuvant Treatment for HER2-Positive Breast Cancer Disclosed

Led by Professor Qiang Liu and Professor Yaping Yang from the Sun Yat-sen Memorial Hospital's Breast Tumor Hospital at Sun Yat-sen University, the final clinical study results of a new neoadjuvant treatment regimen for HER2-positive breast cancer were disclosed for the first time. The results were presented in the form of a POSTER at the SABCS conference to scholars worldwide. The study demonstrates that the regimen, based on pegylated liposomal doxorubicin as part of the AC*4 protocol followed by a T*4 chemotherapy regimen combined with a full-course dual-target treatment, offers good antitumor efficacy and cardiac safety as a neoadjuvant treatment for patients with HER2-positive breast cancer. This article introduces the research.
SABCS Voice of China | Teams led by Professors Yuanting Gu and Jingruo Li Announce Results of CDK4/6 Inhibitor Combined with Letrozole as Neoadjuvant Treatment for Early or Locally Advanced HR+/HER2- Breast Cancer

SABCS Voice of China | Teams led by Professors Yuanting Gu and Jingruo Li Announce Results of CDK4/6 Inhibitor Combined with Letrozole as Neoadjuvant Treatment for Early or Locally Advanced HR+/HER2- Breast Cancer

The results of a single-arm, multicenter, prospective exploratory clinical study on the neoadjuvant treatment of HR-positive, HER2-negative (HR+/HER2-) breast cancer with Dalpiciclib combined with Letrozole, led by Professor Yuanting Gu and Professor Jingruo Li from the First Affiliated Hospital of Zhengzhou University, were selected for poster presentation at the 2023 SABCS conference. The unveiling of these results has attracted widespread attention. The study shows that for patients with early or locally advanced HR+/HER2- breast cancer, the objective response rate (ORR) of Dalpiciclib combined with Letrozole is 81%. Furthermore, an evaluation of the treatment's effectiveness after 4 cycles holds potential as an optional scheme for neoadjuvant chemotherapy-free treatment. This publication has invited Professor Hong Zong from the First Affiliated Hospital of Zhengzhou University to provide a detailed introduction to this study.